Metformin therapy and risk of cancer in patients after heart
transplantation

J 2021

Metformin therapy and risk of cancer in patients after heart transplantation

BEDANOVA, H., V. HORVATH, J. ONDRASEK, Jan KREJČÍ, Petr DOBŠÁK et. al.

Základní údaje

Originální název

Metformin therapy and risk of cancer in patients after heart transplantation

Autoři

BEDANOVA, H. (203 Česká republika, garant), V. HORVATH (203 Česká republika), J. ONDRASEK (203 Česká republika), Jan KREJČÍ (203 Česká republika, domácí), Petr DOBŠÁK (203 Česká republika, domácí) a P. NEMEC

Vydání

Bratislava Medical Journal - Bratislavské lekárske listy, BRATISLAVA, Univerzita Komenského, 2021, 0006-9248

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.564

Kód RIV

RIV/00216224:14110/21:00124032

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/BLL_2021_051

UT WoS

000647174500002

Klíčová slova anglicky

biguanide; heart graft; malignancy; diabetes mellitus; survival

Štítky

14110115, 14110118, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 2. 2022 14:11, Mgr. Tereza Miškechová

Anotace

V originále

BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk

Citovat

BEDANOVA, H., V. HORVATH, J. ONDRASEK, Jan KREJČÍ, Petr DOBŠÁK a P. NEMEC. Metformin therapy and risk of cancer in patients after heart transplantation. Bratislava Medical Journal - Bratislavské lekárske listy. BRATISLAVA: Univerzita Komenského, 2021, roč. 122, č. 5, s. 305-309. ISSN 0006-9248. Dostupné z: https://dx.doi.org/10.4149/BLL_2021_051.

@article{1830786,
   author = {Bedanova, H. and Horvath, V. and Ondrasek, J. and Krejčí, Jan and Dobšák, Petr and Nemec, P.},
   article_location = {BRATISLAVA},
   article_number = {5},
   doi = {http://dx.doi.org/10.4149/BLL_2021_051},
   keywords = {biguanide; heart graft; malignancy; diabetes mellitus; survival},
   language = {eng},
   issn = {0006-9248},
   journal = {Bratislava Medical Journal - Bratislavské lekárske listy},
   title = {Metformin therapy and risk of cancer in patients after heart transplantation},
   url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1},
   volume = {122},
   year = {2021}
}

TY  - JOUR
ID  - 1830786
AU  - Bedanova, H. - Horvath, V. - Ondrasek, J. - Krejčí, Jan - Dobšák, Petr - Nemec, P.
PY  - 2021
TI  - Metformin therapy and risk of cancer in patients after heart transplantation
JF  - Bratislava Medical Journal - Bratislavské lekárske listy
VL  - 122
IS  - 5
SP  - 305-309
EP  - 305-309
PB  - Univerzita Komenského
SN  - 00069248
KW  - biguanide
KW  - heart graft
KW  - malignancy
KW  - diabetes mellitus
KW  - survival
UR  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1
N2  - BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk
ER  -

BEDANOVA, H., V. HORVATH, J. ONDRASEK, Jan KREJČÍ, Petr DOBŠÁK a P. NEMEC. Metformin therapy and risk of cancer in patients after heart transplantation. \textit{Bratislava Medical Journal - Bratislavské lekárske listy}. BRATISLAVA: Univerzita Komenského, 2021, roč.~122, č.~5, s.~305-309. ISSN~0006-9248. Dostupné z: https://dx.doi.org/10.4149/BLL\_{}2021\_{}051.

Podrobný výpis o publikaci